Drug-induced endocrinopathies and diabetes: A combo-endocrinology overview
Ημερομηνία
2019Γλώσσα
en
Λέξη-κλειδί
Επιτομή
In the currently overwhelming era of polypharmacy, the balance of the dynamic and delicate endocrine system can easily be disturbed by interfering pharmaceutical agents like medications. Drugs can cause endocrine abnormalities via different mechanisms, including direct alteration of hormone production, changes in the regulation of the feedback axis, on hormonal transport, binding and signaling, as well as similar changes to counter-regulatory hormone systems. Furthermore, drugs can interfere with the hormonal assays, leading to erroneous laboratory results that disorientate clinicians from the right diagnosis. The purpose of this review is to cover a contemporary topic, the drug-induced endocrinopathies, which was presented in the monothematic annual Combo Endo Course 2018. This challenging part of endocrinology is constantly expanding particularly during the last decade, with the new oncological therapeutic agents, targeting novel molecular pathways in the process of malignancies. In this new context of drug-induced endocrine disease, clinicians should be aware that drugs can cause endocrine abnormalities via different mechanisms and mimic a variety of clinical scenarios. Therefore, it is extremely important for clinicians not only to promptly recognize drug-induced hormonal and metabolic abnormalities, but also to address the therapeutic issues for timely intervention. © 2019 European Society of Endocrinology.
Collections
Related items
Showing items related by title, author, creator and subject.
-
Orbital cellulitis
Tsirouki T., Dastiridou A.I., Ibánez flores N., Cerpa J.C., Moschos M.M., Brazitikos P., Androudi S. (2018)Orbital cellulitis (OC) is an inflammatory process that involves the tissues located posterior to the orbital septum within the bony orbit, but the term generally is used to describe infectious inflammation. It manifests ... -
Expert consensus on the rational clinical use of proprotein convertase subtilisin/kexin type 9 (PCSK9) inhibitors
Achimastos A., Alexandrides T., Alexopoulos D., Athyros V., Bargiota A., Bilianou E., Chrysochoou C., Drogari E., Elisaf M., Ganotakis E., Goudevenos I., Ioannidis I., Kolovou G., Kotsis V., Lekakis I., Liberopoulos E., Melidonis A., Nikolaou V., Ntaios G., Papanas N., Pappas S., Pitsavos C., Rallidis L., Richter D., Skoumas I., Tentolouris N., Tousoulis D., Tselepis A., Tsioufis K., Tziakas D., Tziomalos K., Vardas P., Vlachopoulo C., Vlahakos D. (2016)Two proprotein convertase subtilisin/kexin type 9 (PCSK9) inhibitors, evolocumab and alirocumab, have recently been approved by both the Food and Drug Administration (FDA) and the European Medicines Agency (EMA) for the ... -
Hypothalamic inflammation as a potential pathophysiologic basis for the heterogeneity of clinical, hormonal, and metabolic presentation in pcos
Barlampa D., Bompoula M.S., Bargiota A., Kalantaridou S., Mastorakos G., Valsamakis G. (2021)Polycystic ovary syndrome (PCOS) is the most common endocrine disorder among women of reproductive age. It is a heterogeneous condition characterized by reproductive, endocrine, metabolic, and psychiatric abnormalities. ...